EU Orphan And Pediatric Proposals Insufficient, Says Industry
Executive Summary
Innovators warn against slashing incentives and argue a lack of a common definition of unmet need is a stumbling block to proposals.
You may also be interested in...
Long-Awaited EU Review Questions 10-Year Orphan Exclusivity
The EU Orphan Regulation and the Paediatric Regulation have helped to increase the number of products developed for rare diseases and children, but they both have some shortcomings that need to be addressed, according to an evaluation of the legislation carried out by the EU authorities. The European pharmaceutical industry has warned against opening up the legislation, saying it is “critical to maintain a stable and predictable incentives framework."
Brazil Authorizes Oxford/AZ and Sinovac Vaccines
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
Success For Dutch Parallel Registration and Reimbursement Pilot
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: